Borhane Slama
Overview
Explore the profile of Borhane Slama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rombaut D, Sandmann S, Tekath T, Crouch S, de Graaf A, Smith A, et al.
Hemasphere
. 2025 Jan;
9(1):e70073.
PMID: 39850648
Lower risk (LR) myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem and progenitor disorders caused by the accumulation of somatic mutations in various genes including epigenetic regulators that may produce convergent...
2.
Lefevre G, Bleuse S, Puyade M, Moulis G, Neel A, Abisror N, et al.
Allergy
. 2025 Jan;
PMID: 39757773
Background: Hypereosinophilic syndromes (HES) are a heterogenous group of eosinophilic disorders. To date, only retrospective studies of limited sample-size and/or follow-up duration are available. Methods: The COHESion study is a...
3.
Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al.
Nat Med
. 2024 Jun;
30(8):2235-2241.
PMID: 38830994
CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of...
4.
Dartigeas C, Quinquenel A, Ysebaert L, Dilhuydy M, Anglaret B, Slama B, et al.
Ann Hematol
. 2024 Mar;
PMID: 38443660
We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five...
5.
Noel R, Zemmour C, Montes de Oca C, Belmecheri N, Aurran-Schleinitz T, Coso D, et al.
Hematology
. 2023 May;
28(1):2207948.
PMID: 37133334
Relapsed/Refractory Diffuse Large B Cell Lymphoma have a dismal prognosis in need of innovative treatments. This prospective phase 2 study enrolled 32 patients between 2013 and 2017 with Relapsed/Refractory Diffuse...
6.
Cartron G, Bachy E, Tilly H, Daguindau N, Pica G, Bijou F, et al.
J Clin Oncol
. 2023 Apr;
41(19):3523-3533.
PMID: 37071836
Purpose: Rituximab improves progression-free survival (PFS) and time to next treatment (TTNT) when compared with the watch and wait strategy for patients with low-tumor burden follicular lymphoma (FL). Prolonged rituximab...
7.
Bishton M, Salles G, Golfier C, Knauf W, Bocchia M, Turner D, et al.
EJHaem
. 2023 Feb;
4(1):45-54.
PMID: 36819165
The rituximab biosimilar CT-P10 is approved for the treatment of non-Hodgkin lymphoma. Previous studies have demonstrated clinical similarity between CT-P10 and reference rituximab. However, real-world data relating to treatment in...
8.
Dumontet C, Demangel D, Galia P, Karlin L, Roche L, Fauvernier M, et al.
Am J Hematol
. 2023 Jan;
98(2):264-271.
PMID: 36588407
Familial forms of monoclonal gammopathy, defined as multiple myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS), are relatively infrequent and most series reported in the literature describe a limited...
9.
Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, et al.
Blood
. 2022 Nov;
141(11):1308-1315.
PMID: 36375118
Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs, with which del(1p32) appears...
10.
Dartigeas C, Slama B, Doyle M, Tapprich C, Albrecht C, Dupuis S, et al.
Clin Hematol Int
. 2022 Sep;
4(3):65-74.
PMID: 36103041
The FIRE study investigated the real-world effectiveness and safety of ibrutinib in prospectively observed patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) in France....